

Management of Immune-Related Adverse Events in Patient Receptor T-Cell Therapy: ASCO Guideline

Journal of Clinical Oncology

39, 3978-3992

DOI: [10.1200/jco.21.01992](https://doi.org/10.1200/jco.21.01992)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ASCO releases guideline on CAR T-cell therapy. <i>Cancer</i> , 2022, 128, 429-430.	4.1	3
2	Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100272.	1.1	3
3	Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. <i>Cytotherapy</i> , 2022, 24, 742-749.	0.7	2
4	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 836452.	2.8	5
5	Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3012.	4.1	6
6	Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. <i>Frontiers in Oncology</i> , 2022, 12, 841117.	2.8	9
7	Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem. <i>Cancers</i> , 2022, 14, 1501.	3.7	43
8	Gastric Cancer Cell-Derived Kynurenines Hyperactive Regulatory T Cells to Promote Chemoresistance via the IL-10/STAT3/BCL2 Signaling Pathway. <i>DNA and Cell Biology</i> , 2022, 41, 447-455.	1.9	6
9	Reply to M.B. Abid. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200225.	1.6	0
10	Granulocyte Colony-Stimulating Factor Usage in Recipients of Chimeric Antigen Receptor T-Cell Immunotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 1508-1509.	1.6	3
11	Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. <i>Blood Advances</i> , 2022, 6, 3398-3403.	5.2	17
12	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	4.9	124
13	Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 405.	4.1	11
14	An update on novel multiple myeloma targets. <i>Expert Review of Hematology</i> , 2022, 15, 519-537.	2.2	1
15	Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 673-686.	3.8	3
16	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	3.8	29
17	Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 315-329.	1.6	3
18	Stage 4 Cytokine Release Syndrome Caused by the First Dose of Nivolumab and Ipilimumab Combination Therapy in a Patient with Metastatic Melanoma Successfully Treated with Methylprednisolone, Tocilizumab, and Etanercept. <i>Case Reports in Oncology</i> , 2022, 15, 648-653.	0.7	7

#	ARTICLE	IF	CITATIONS
19	Chimeric antigen receptor T-cell therapy in adults: management of toxicities and implications for critical care. <i>BJA Education</i> , 2022, 22, 330-333.	1.4	1
20	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. <i>Clinical Cancer Research</i> , 2022, 28, 3804-3813.	7.0	17
21	Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. <i>Drug Safety</i> , 2022, 45, 891-908.	3.2	18
22	Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 4821-4830.	5.2	20
23	Current status and prospects of hematopoietic stem cell transplantation in China. <i>Chinese Medical Journal</i> , 2022, 135, 1394-1403.	2.3	7
24	A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 31-43.	0.4	0
25	Hemophagocytic lymphohistiocytosis secondary to CAR-T cells: Update from the FDA and Vizient databases. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7
26	Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086.	3.7	3
27	CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. <i>Biomedicines</i> , 2022, 10, 1960.	3.2	5
28	A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8600.	4.1	6
29	Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 1973-1976.	2.8	6
30	Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 19-26.	1.2	2
31	Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 180, 103826.	4.4	6
32	Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity. <i>Seminars in Nuclear Medicine</i> , 2023, 53, 18-36.	4.6	5
33	Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	52
34	Whole-process management of complications during CAR-T therapy. , 2022, 1, .		0
35	The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7
36	Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	19

#	ARTICLE	IF	CITATIONS
37	Toxicities following CAR-T therapy for hematological malignancies. <i>Cancer Treatment Reviews</i> , 2022, 111, 102479.	7.7	13
38	Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells. <i>British Journal of Haematology</i> , 2023, 201, 86-94.	2.5	4
39	Neurological Complications of Conventional and Novel Anticancer Treatments. <i>Cancers</i> , 2022, 14, 6088.	3.7	9
40	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1845-1860.	3.0	2
42	Advancing CAR T cell therapy through the use of multidimensional omics data. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 211-228.	27.6	30
45	Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma. <i>Annals of Hematology</i> , 2023, 102, 967-969.	1.8	1
46	Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. <i>Biomolecules</i> , 2023, 13, 382.	4.0	8
47	Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
48	Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. <i>Blood Research</i> , 2023, 58, S20-S28.	1.3	3
49	Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
50	Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
52	Cytokine Storm Syndromes in Pediatric Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, , .	3.8	1
53	RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines. <i>Investigational New Drugs</i> , 2023, 41, 220-225.	2.6	1
54	Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 440-448.	1.2	9
55	Anti-CD119-based CAR T cells with anti-CD119 or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia. <i>Cancer Medicine</i> , 2023, 12, 9655-9661.	2.8	7
56	Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients. <i>BMC Cancer</i> , 2023, 23, .	2.6	13
57	Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. <i>Current Oncology</i> , 2023, 30, 5003-5023.	2.2	1
58	Fatal cytokine-release syndrome in a patient receiving toripalimab: a case report. <i>Immunotherapy</i> , 2023, 15, 641-645.	2.0	1

#	ARTICLE	IF	CITATIONS
59	Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
60	Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology. <i>Neoplasia</i> , 2023, 42, 100909.	5.3	1
61	Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. <i>Lancet Oncology</i> , The, 2023, 24, e255-e269.	10.7	20
62	Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti-CD19 chimeric antigen receptor T cell therapy. <i>Hematological Oncology</i> , 2023, 41, 933-941.	1.7	0
63	Thermoresponsive Polypeptide Fused Asparaginase with Mitigated Immunogenicity and Enhanced Efficacy in Treating Hematologic Malignancies. <i>Advanced Science</i> , 0, , .	11.2	1
64	Cytomegalovirus infection in chimeric antigen receptor T-cell recipients. <i>Journal of the American Association of Nurse Practitioners</i> , 0, Publish Ahead of Print, .	0.9	0
65	Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2023, 389, 899-910.	27.0	56
66	Neurologic Complications of Cancer Immunotherapy. <i>Current Oncology</i> , 2023, 30, 5876-5897.	2.2	0
67	Early and Late Toxicities of Chimeric Antigen Receptor T-Cells. <i>Hematology/Oncology Clinics of North America</i> , 2023, , .	2.2	0
68	Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	5
69	Thinking Clearly with Anakinra. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 406-407.	1.2	0
70	Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
71	Managing Adverse Effects of Novel Therapeutic Agents in Gynecologic Malignancies. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.6	0
72	A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
73	Noninfectious causes of fever in hematologic malignancies. Are antibiotics still indicated?. <i>Current Opinion in Infectious Diseases</i> , 2023, 36, 209-217.	3.1	0
74	Single-Cell Transcriptomics for Unlocking Personalized Cancer Immunotherapy: Toward Targeting the Origin of Tumor Development Immunogenicity. <i>Cancers</i> , 2023, 15, 3615.	3.7	2
75	The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 1271-1285.	0.9	10
76	The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). <i>Arthritis and Rheumatology</i> , 2023, 75, 1714-1732.	5.6	2

#	ARTICLE	IF	CITATIONS
77	Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 1319-1331.	4.1	0
78	Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T cells (CAR-T): A comprehensive review on incidence, risk factors and current management. <i>European Journal of Haematology</i> , 2024, 112, 184-196.	2.2	3
79	Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	5.0	1
80	Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM). <i>Cancers</i> , 2023, 15, 4028.	3.7	0
81	Early antibiotic de-escalation and discontinuation in Patients with Febrile Neutropenia after Cellular Therapy: A Single Center Prospective Unblinded Randomized Trial. <i>Transplantation and Cellular Therapy</i> , 2023, , .	1.2	0
82	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	5
83	Infections after chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies. <i>Transplant Infectious Disease</i> , 2023, 25, .	1.7	5
84	Long-term survivorship care after CAR-T cell therapy. <i>European Journal of Haematology</i> , 2024, 112, 41-50.	2.2	2
85	Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. <i>Journal of Biomedical Science</i> , 2023, 30, .	7.0	0
86	Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)-T cell therapy in patients with hematological malignancy. <i>European Journal of Haematology</i> , 2024, 112, 257-265.	2.2	0
87	Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future. <i>Journal of Clinical Oncology</i> , 2023, 41, 4416-4429.	1.6	13
88	Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapy. <i>European Journal of Haematology</i> , 2024, 112, 111-121.	2.2	1
89	Severe persistent neurotoxicity associated with CAR-T therapy in children. <i>British Journal of Haematology</i> , 0, , .	2.5	0
91	Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report. <i>Internal Medicine</i> , 2023, , .	0.7	2
92	CAR-T Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented Review. <i>Clinical Pharmacology and Therapeutics</i> , 0, , .	4.7	2
93	IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy. <i>Annals of Hematology</i> , 0, , .	1.8	0
94	INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities. <i>Transplantation and Cellular Therapy</i> , 2024, 30, 38-55.	1.2	1
95	Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy. <i>Current Neurology and Neuroscience Reports</i> , 0, , .	4.2	0

#	ARTICLE	IF	CITATIONS
96	Intrathecal hydrocortisone for treatment of children and young adults with CAR Tâ€cell immuneâ€effector cellâ€associated neurotoxicity syndrome. <i>Pediatric Blood and Cancer</i> , 2024, 71, .	1.5	0
97	A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist. <i>Journal of Intensive Care Medicine</i> , 0, , .	2.8	0
98	Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. <i>Rheumatology</i> , 0, , .	1.9	1
99	Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer. <i>International Immunopharmacology</i> , 2023, 125, 111093.	3.8	0
100	The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy. <i>Blood Reviews</i> , 2024, 63, 101141.	5.7	0
101	CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 1595.	2.5	0
102	Building safety into CAR-T therapy. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	1
103	CAR-T cell therapy: Where are we now, and where are we heading?. <i>Blood Science</i> , 2023, 5, 237-248.	0.9	0
104	Oncogenic viral antigens for engineered T cell immunotherapy: Challenges and opportunities. , 2023, 1, 306-317.		0
105	Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. <i>Hematology American Society of Hematology Education Program</i> , 2023, 2023, 77-83.	2.5	1
106	Patterns of neurotoxicity among patients receiving chimeric antigen receptor Tâ€cell therapy: A singleâ€centre cohort study. <i>European Journal of Neurology</i> , 2024, 31, .	3.3	0
107	A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
108	Rapid anti-myeloma activity by Tâ€cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. <i>Molecular Therapy</i> , 2024, 32, 503-526.	8.2	0
109	The predictive value of peripheral blood CD4 cells ATP concentration for immune-related adverse events in advanced non-small cell lung cancer patients. <i>BMC Immunology</i> , 2024, 25, .	2.2	0
110	Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients â€“ A case report and review of the literature. <i>Heliyon</i> , 2024, 10, e24380.	3.2	0
111	Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies. <i>Annals of Laboratory Medicine</i> , 2024, 44, 210-221.	2.5	1
112	Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4 ⁺ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma. , 2024, 12, e008056.		0
113	Longitudinal plasma proteomics in CAR Tâ€cell therapy patients implicates neutrophils and NETosis in the genesis of CRS. <i>Blood Advances</i> , 2024, 8, 1422-1426.	5.2	0

#	ARTICLE	IF	CITATIONS
115	Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2024, 24, e217-e225.	0.4	0
116	Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies. , 2024, , .		0
117	Immune Effector Cell-Associated Neurotoxicity Syndrome Related to Chimeric Antigen Receptor T-Cell Therapy. <i>Neurology</i> , 2024, 102, .	1.1	0
118	Intrathecal bivalent CAR T cells targeting EGFR and IL13R α 2 in recurrent glioblastoma: phase 1 trial interim results. <i>Nature Medicine</i> , 0, , .	30.7	0
119	In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines. <i>Clinical and Translational Science</i> , 2024, 17, .	3.1	0
120	Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK. <i>British Journal of Anaesthesia</i> , 2024, 132, 1004-1006.	3.4	0
121	[18F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	6.4	0